BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 224 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q2 2021. The put-call ratio across all filers is 1.19 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $480,000 | -90.1% | 3,174 | -90.4% | 0.00% | -100.0% |
| Q2 2022 | $4,838,000 | +36.7% | 33,204 | +11.2% | 0.00% | +50.0% |
| Q1 2022 | $3,539,000 | -3.3% | 29,849 | +12.5% | 0.00% | 0.0% |
| Q4 2021 | $3,658,000 | +469.8% | 26,544 | +474.7% | 0.00% | – |
| Q3 2021 | $642,000 | +75.9% | 4,619 | +22.7% | 0.00% | – |
| Q2 2021 | $365,000 | +54.0% | 3,763 | +8.5% | 0.00% | – |
| Q1 2021 | $237,000 | +2.6% | 3,469 | +28.8% | 0.00% | – |
| Q4 2020 | $231,000 | -10.5% | 2,693 | -23.8% | 0.00% | – |
| Q2 2020 | $258,000 | +29.0% | 3,535 | -8.8% | 0.00% | – |
| Q1 2019 | $200,000 | +316.7% | 3,877 | +216.2% | 0.00% | – |
| Q2 2018 | $48,000 | +71.4% | 1,226 | +12.9% | 0.00% | – |
| Q1 2018 | $28,000 | +100.0% | 1,086 | +103.4% | 0.00% | – |
| Q4 2017 | $14,000 | -65.9% | 534 | -51.1% | 0.00% | – |
| Q3 2017 | $41,000 | +64.0% | 1,093 | +10.5% | 0.00% | – |
| Q2 2017 | $25,000 | – | 989 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 1,111,111 | $107,867,000 | 52.60% |
| Knoll Capital Management, LLC | 856,844 | $83,182,000 | 43.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,082,555 | $202,174,000 | 27.86% |
| ARS Investment Partners, LLC | 558,286 | $54,198,000 | 5.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $17,113,000 | 4.52% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 401,006 | $38,930,000 | 4.51% |
| Eventide Asset Management | 1,990,797 | $193,267,000 | 2.60% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 56,626 | $5,497,000 | 2.45% |
| Avidity Partners Management LP | 882,500 | $85,673,000 | 2.32% |
| Nicholas Investment Partners, LP | 363,708 | $35,309,000 | 2.22% |